

August 30, 2017

FOR IMMEDIATE RELEASE

Gravis Receives Conditional Approval for Fundamental Change

Vancouver, British Columbia – August 30, 2017 – Gravis Energy Corp. (CNSX: GVE) (the “**Company**”) and BiocurePharm Corporation (“**BiocurePharm**”) announce that Gravis has received conditional acceptance from the Canadian Securities Exchange (“CSE”) for its proposed acquisition by the Company of all of the issued and outstanding securities of BiocurePharm (the “**Transaction**”), which is a ‘fundamental change’ within the meaning of the applicable policies of the CSE. For additional details concerning the Transaction, please refer to the Company’s news release dated March 22, 2017.

The conditions for the Company to receive the final approval of the CSE include obtaining shareholder approval and submitting all final remaining listing documentation and fees. The Company intends to seek shareholder approval by way of written consent, which it expects to receive within the next 14 days.

As previously announced, prior to the closing, the Company will consolidate its share capital on a 6.033479 old for one new basis (the “**Consolidation**”) and will acquire all of the issued and outstanding securities of BiocurePharm in consideration of the issuance of common shares of the Company on the basis of 24 post-Consolidation common shares of the Company being issued for each share of BiocurePharm held. Upon completion of the Transaction, the Company will change its name to “Biocure Technology Inc.” and its stock symbol will be changed to “CURE”. The Company will announce the effective dates for the Consolidation and change of name once finalized.

The Company anticipates that the closing of the Transaction will occur late in September to allow sufficient time for the corporate law procedures by which the Company will acquire BiocurePharm to be completed under Korean law. The Company’s shares will remain halted until the final approval of the CSE is received.

About the Company

Gravis Energy Corp. (CNSX: GVE) is a Canadian based uranium exploration and development company which has a property in Athabasca Basin, Saskatchewan. Gravis Energy Corp. has a 10% interest in a Korean consortium which includes Korea Hydro & Nuclear Power Co. Ltd., Korea Nuclear Fuel Co. Ltd., and Hanwha Corporation.

About BiocurePharm

BiocurePharm is a private South Korean based Bio Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. BiocurePharm is in the process of clinical trials of five major biosimilar products in South Korea, including Interferon Beta 1b, Filgrastim and Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (“MS”) Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration. It is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes.

BiocurePharm is also developing a foot and mouth disease vaccine, a hair growth production product and a breast cancer detection kit.

ON BEHALF OF THE BOARD OF DIRECTORS

/s/ "Julie Hajduk"
CEO and Director

For further information, please contact:

Gravis Energy Corp. Telephone: 1-778-331-3816

Not for distribution to United States wire services or dissemination in the United States. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Certain statements in this news release, which are not historical in nature, constitute "forward looking statements" within the meaning of that phrase under applicable Canadian securities law. These statements include, but are not limited to, statements or information concerning likelihood of the completion of the Transaction, Consolidation and name change, the Company's business activities following the completion of the Transaction, the timing of any of the Company's performance or events. These statements reflect management's current assumptions and expectations and by their nature are subject to certain underlying assumptions, known and unknown risks and uncertainties and other factors which may cause actual results, performance or events to be materially different from those expressed or implied by such forward looking statements. Except as required pursuant to applicable securities laws, the Company will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by the Company. Readers are cautioned not to place undue reliance on forward looking statements.

Neither the Canadian Securities Exchange (the "CSE") nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Completion of the transaction disclosed herein is subject to a number of conditions, including but not limited to, CSE acceptance and if applicable pursuant to requirements of the CSE, and shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.